PD-1/PD-L1 and VEGF/VEGFR antibody regimens significantly improve survival in advanced NSCLC
Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR in advanced or metastatic NSCLC: a meta-analysis of RCTs.
Abstract
Meta-analysis of 11 RCTs found antibody regimens targeting PD-1/PD-L1 and VEGF/VEGFR improved PFS (HR=0.65) and OS (HR=0.79) in advanced NSCLC patients.